Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab for BCG-refractory bladder CIS
NCT02901548Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2017
- Primary completion
- Jul 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in urothelial carcinoma in situ of the bladder (CIS), sponsored by Moffitt Cancer Center. Primary endpoint: Complete Response Rate at 6 Months. Started Feb 2017; status: terminated.
02
Drugs
durvalumab
03
Conditions
urothelial carcinoma in situ of the bladder (CIS)
Beyond the preview
Go deeper on NCT02901548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901548.